Paper Details

  1. Home
  2. Paper Details

Antitumor activity and safety of tivozanib (AV-951) in a phase II randomized discontinuation trial in patients with renal cell carcinoma.

Author: AnischenkoA A, BhargavaPankaj, ChackoRaju T, DovalDinesh C, EstevesBrooke, LipatovOleg N, LyulkoAlexei A, NosovDmitry A, SlichenmyerWilliam J, StrahsAndrew

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This phase II, randomized discontinuation trial evaluated the antitumor activity and safety of tivozanib in patients with advanced/metastatic renal cell carcinoma (RCC). Tivozanib demonstrated objective response rates of 18% at 16 weeks and 24% overall. The median progression-free survival was 11.7 months. The most common grade 3 and 4 treatment-related adverse event was hypertension (12%).
Paper Details　
Original Abstract of the Article :
PURPOSE: The antitumor activity and safety of tivozanib, which is a potent and selective vascular endothelial growth factor receptor-1, -2, and -3 inhibitor, was assessed in patients with advanced/metastatic renal cell carcinoma (RCC). PATIENTS AND METHODS: In this phase II, randomized discontinuat...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1200/JCO.2011.35.3524

データ提供：米国国立医学図書館（NLM）

Tivozanib: A New Oasis in the Desert of Renal Cell Carcinoma

Renal cell carcinoma, a type of kidney cancer, can be a relentless force, like a desert storm threatening to engulf the body. This study, published in 2012, investigates the antitumor activity and safety of tivozanib, a novel drug that targets vascular endothelial growth factor receptors, which play a critical role in tumor growth and spread. It's like seeking a hidden oasis in the desert, a source of strength to combat the disease.

The researchers conducted a phase II randomized discontinuation trial with 272 patients with advanced/metastatic renal cell carcinoma. Their findings suggest that tivozanib is a well-tolerated and effective treatment, demonstrating significant antitumor activity and prolonging progression-free survival.

Tivozanib: A Promising Weapon in the Fight Against Renal Cell Carcinoma

The study demonstrates that tivozanib is a valuable addition to the armamentarium for treating renal cell carcinoma. It's like discovering a new weapon in the battle against a desert storm, offering a beacon of hope for those facing this challenging disease. The researchers highlight the need for further research to optimize tivozanib's use and explore its potential in combination with other therapies.

Living with Renal Cell Carcinoma: Seeking New Hope and Treatment Options

This research offers hope to those living with renal cell carcinoma, demonstrating that new treatment options can significantly impact the course of the disease. It's a journey of perseverance, like navigating a treacherous desert, knowing that with each step we come closer to a brighter future.

Dr.Camel's Conclusion

The study underscores the importance of ongoing research in the fight against cancer, demonstrating the potential of targeted therapies like tivozanib to improve treatment outcomes for patients. It's a journey of discovery and innovation, like exploring a vast desert, always seeking new ways to combat disease and improve patient well-being.

Date :
  1. Date Completed 2012-07-12
  2. Date Revised 2014-11-20
Further Info :

Pubmed ID

22493422

DOI: Digital Object Identifier

10.1200/JCO.2011.35.3524

Related Literature

Article Analysis
・Side Effects of tivozanib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.